Loading...

Applied Genetic Technologies

DB:2GT
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2GT
DB
$83M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The last earnings update was 73 days ago. More info.


Add to Portfolio Compare Print
  • Applied Genetic Technologies has significant price volatility in the past 3 months.
2GT Share Price and Events
7 Day Returns
0.5%
DB:2GT
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
1.4%
DB:2GT
-10.2%
DE Biotechs
-6%
DE Market
2GT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Applied Genetic Technologies (2GT) 0.5% 5.1% 59.5% 1.4% -72.7% -55.3%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 2GT outperformed the Biotechs industry which returned -10.2% over the past year.
  • 2GT outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
2GT
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Applied Genetic Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Applied Genetic Technologies. This is due to cash flow or dividend data being unavailable. The share price is €4.035.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Applied Genetic Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Applied Genetic Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2GT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.98
NasdaqGM:AGTC Share Price ** NasdaqGM (2019-04-18) in USD $4.55
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Applied Genetic Technologies.

DB:2GT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:AGTC Share Price ÷ EPS (both in USD)

= 4.55 ÷ -0.98

-4.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Applied Genetic Technologies is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Applied Genetic Technologies is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Applied Genetic Technologies's expected growth come at a high price?
Raw Data
DB:2GT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.66x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-18.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Applied Genetic Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Applied Genetic Technologies's assets?
Raw Data
DB:2GT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.18
NasdaqGM:AGTC Share Price * NasdaqGM (2019-04-18) in USD $4.55
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:2GT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:AGTC Share Price ÷ Book Value per Share (both in USD)

= 4.55 ÷ 4.18

1.09x

* Primary Listing of Applied Genetic Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Applied Genetic Technologies is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Applied Genetic Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Applied Genetic Technologies has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Applied Genetic Technologies expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-18.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Applied Genetic Technologies expected to grow at an attractive rate?
  • Unable to compare Applied Genetic Technologies's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Applied Genetic Technologies's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Applied Genetic Technologies's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2GT Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2GT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -18.2%
DB:2GT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 0.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2GT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2GT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-06-30 14 -60 1
2022-06-30 49 -73 1
2021-06-30 32 -68 1
2020-06-30 40 -62 1
2019-06-30 27 -33 -29 3
DB:2GT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 29 -23 -18
2018-09-30 28 -23 -19
2018-06-30 24 -33 -21
2018-03-31 27 -36 -18
2017-12-31 32 -37 -11
2017-09-30 38 -34 -4
2017-06-30 39 -31 0
2017-03-31 43 -28 6
2016-12-31 47 -28 10
2016-09-30 48 -30 11
2016-06-30 47 71 -1
2016-03-31 36 72 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Applied Genetic Technologies is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Applied Genetic Technologies's revenue is expected to grow by 0.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2GT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Applied Genetic Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2GT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-06-30 -1.56 -1.39 -1.72 2.00
2022-06-30 -1.90 -1.88 -1.91 2.00
2021-06-30 -1.92 -1.87 -1.97 2.00
2020-06-30 -2.45 -2.10 -2.95 4.00
2019-06-30 -1.39 -1.10 -1.78 4.00
DB:2GT Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.98
2018-09-30 -1.03
2018-06-30 -1.18
2018-03-31 -0.99
2017-12-31 -0.61
2017-09-30 -0.22
2017-06-30 0.02
2017-03-31 0.35
2016-12-31 0.53
2016-09-30 0.60
2016-06-30 -0.08
2016-03-31 -0.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Applied Genetic Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Applied Genetic Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Applied Genetic Technologies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Applied Genetic Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Applied Genetic Technologies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Applied Genetic Technologies does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Applied Genetic Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Applied Genetic Technologies's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Applied Genetic Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Applied Genetic Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2GT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 28.99 -17.69 13.55 16.82
2018-09-30 27.91 -18.70 13.90 16.82
2018-06-30 24.19 -21.30 14.39 16.82
2018-03-31 27.12 -17.89 13.87 14.99
2017-12-31 31.90 -10.98 12.84 14.99
2017-09-30 37.98 -4.02 12.21 14.99
2017-06-30 39.47 0.41 11.35 14.99
2017-03-31 43.24 6.33 10.87 10.98
2016-12-31 46.85 9.50 10.31 10.98
2016-09-30 48.11 10.77 10.13 10.98
2016-06-30 47.36 -1.38 10.07 10.98
2016-03-31 35.96 -12.07 10.32
2015-12-31 24.25 -20.37 10.53
2015-09-30 12.71 -28.06 9.87
2015-06-30 2.35 -24.32 8.77 0.91
2015-03-31 1.77 -20.88 8.02
2014-12-31 1.71 -18.14 6.81
2014-09-30 1.58 -14.23 6.08
2014-06-30 1.13 -15.91 5.18
2014-03-31 1.38 -12.82 3.77
2013-12-31 1.27 -10.85 2.73
2013-09-30 0.94 -11.45 1.90
2013-06-30 0.94 -4.99 1.40
2012-06-30 1.08 -1.92 0.79

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Applied Genetic Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Applied Genetic Technologies has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Applied Genetic Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Applied Genetic Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Applied Genetic Technologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Applied Genetic Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Applied Genetic Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Applied Genetic Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Applied Genetic Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Applied Genetic Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Applied Genetic Technologies has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Applied Genetic Technologies Company Filings, last reported 3 months ago.

DB:2GT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 75.98 0.00 96.08
2018-09-30 78.94 0.00 105.44
2018-06-30 99.18 0.00 104.91
2018-03-31 104.70 0.00 111.80
2017-12-31 111.58 0.00 119.66
2017-09-30 115.40 0.00 125.20
2017-06-30 115.33 0.00 126.70
2017-03-31 118.36 0.00 131.73
2016-12-31 117.93 0.00 117.33
2016-09-30 114.35 0.00 133.32
2016-06-30 109.29 0.00 98.53
2016-03-31 105.11 0.00 133.70
2015-12-31 102.03 0.00 150.02
2015-09-30 97.38 0.00 165.95
2015-06-30 85.53 0.00 61.64
2015-03-31 92.79 0.00 62.28
2014-12-31 98.15 0.00 75.34
2014-09-30 101.94 0.00 90.91
2014-06-30 74.87 0.00 73.07
2014-03-31 27.10 0.00 24.53
2013-12-31 30.07 0.00 28.00
2013-09-30 15.14 0.00 20.86
2013-06-30 22.03 0.00 22.89
2012-06-30 1.31 1.02 0.77
  • Applied Genetic Technologies has no debt.
  • Applied Genetic Technologies had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Applied Genetic Technologies has sufficient cash runway for more than 3 years based on current free cash flow.
  • Applied Genetic Technologies has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 81.1% each year.
X
Financial health checks
We assess Applied Genetic Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Applied Genetic Technologies has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Applied Genetic Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Applied Genetic Technologies dividends.
If you bought €2,000 of Applied Genetic Technologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Applied Genetic Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Applied Genetic Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2GT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2GT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-06-30
2022-06-30
2021-06-30
2020-06-30
2019-06-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Applied Genetic Technologies has not reported any payouts.
  • Unable to verify if Applied Genetic Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Applied Genetic Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Applied Genetic Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Applied Genetic Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Applied Genetic Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Applied Genetic Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Applied Genetic Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sue Washer
COMPENSATION $1,063,568
AGE 57
TENURE AS CEO 17.1 years
CEO Bio

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a strong scientific and operational background. Ms. Washer served as chief operating officer of Applied Genetic Technologies Corp. from October 2001 to March 2002. She has 10 years of pharmaceutical management and research experience. She also served at Abbott Labs and Eli Lilly as well as 11 years of senior management experience at entrepreneurial firms in the Gainesville area. She successfully raised over $15M at AGTC in their second round of funding in November of 2003. From August 1996 to October 2001, Ms. Washer was president and chief executive officer of Scenic Productions Inc., a specialty construction firm providing sculpting, painting and construction services to the entertainment industry. From June 1994 to August 1996, Ms. Washer served as the Founding Executive Director and then Business Advisor for the North Florida Technology Innovation Center, a public-private organization financing and providing services to entrepreneurial companies licensing technology from Florida universities. She served as the Chairman of the Board of Directors at BioFlorida. She serves as a Director of Alliance at Regenerative Medicine. From October 1983 to June 1994, Ms. Washer served in various research and pharmaceutical management positions with Abbott Laboratories and Eli Lilly and Company. She has been a Director of Applied Genetic Technologies, Corporation since November 2003. She has been Director of Histogenics Corporation since April 18, 2018. She serves as a Director of BioFlorida. She is a member of the Executive Committee at UF's Center for Entrepreneurship and Southeast BIO; and a Board Member at the Gainesville Area Chamber of Commerce and the Florida High Tech Corridor Council. Ms. Washer has a B.S. in biochemistry from Michigan State University and an MBA from the University of Florida where she was one of the first graduates from the Business School's Entrepreneurship program.

CEO Compensation
  • Sue's compensation has been consistent with company performance over the past year.
  • Sue's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Applied Genetic Technologies management team in years:

17.1
Average Tenure
51
Average Age
  • The average tenure for the Applied Genetic Technologies management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Sue Washer

TITLE
President
COMPENSATION
$1M
AGE
57
TENURE
17.1 yrs

Bill Sullivan

TITLE
Chief Financial Officer
COMPENSATION
$921K
AGE
47
TENURE
1.7 yrs

Matthew Feinsod

TITLE
Interim Chief Medical Officer
COMPENSATION
$769K
AGE
47
TENURE
1.6 yrs

Nick Muzyczka

TITLE
Co-Founder
TENURE
20.3 yrs

Barry Byrne

TITLE
Co-Founder
TENURE
20.3 yrs

William Hauswirth

TITLE
Co-Founder & Member of Ophthalmology Scientific Advisory Board

Richard Samulski

TITLE
Co-Founder
TENURE
20.3 yrs

Terry Flotte

TITLE
Co-Founder
TENURE
20.3 yrs

Mark Shearman

TITLE
Chief Scientific Officer
COMPENSATION
$1M
AGE
58
TENURE
3.8 yrs

Andrew Ashe

TITLE
General Counsel & Secretary
AGE
51
TENURE
1.7 yrs
Board of Directors Tenure

Average tenure and age of the Applied Genetic Technologies board of directors in years:

6.4
Average Tenure
57
Average Age
  • The tenure for the Applied Genetic Technologies board of directors is about average.
Board of Directors

Scott Koenig

TITLE
Chairman
COMPENSATION
$75K
AGE
66
TENURE
15 yrs

Sue Washer

TITLE
President
COMPENSATION
$1M
AGE
57
TENURE
15.4 yrs

William Hauswirth

TITLE
Co-Founder & Member of Ophthalmology Scientific Advisory Board

Ivana Magovcevic-Liebisch

TITLE
Director
COMPENSATION
$53K
AGE
51
TENURE
4.8 yrs

Anne VanLent

TITLE
Director
COMPENSATION
$50K
AGE
70
TENURE
2.7 yrs

Bill Aliski

TITLE
Director
AGE
72
TENURE
0.6 yrs

Jimmy Rosen

TITLE
Director
COMPENSATION
$40K
AGE
49
TENURE
9.1 yrs

Ed Hurwitz

TITLE
Director
COMPENSATION
$46K
AGE
55
TENURE
6.4 yrs

David Birch

TITLE
Member of Ophthalmology Scientific Advisory Board

Peter Campochiaro

TITLE
Member of Ophthalmology Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
19. Dec 18 Buy James Rosen Individual 14. Dec 18 14. Dec 18 1,000 €2.99 €2,994
19. Dec 18 Buy William Aliski Individual 14. Dec 18 14. Dec 18 6,000 €2.88 €17,245
19. Dec 18 Buy William Sullivan Individual 14. Dec 18 14. Dec 18 3,000 €2.95 €8,845
19. Dec 18 Sell Mark Shearman Individual 14. Dec 18 14. Dec 18 -3,000 €2.97 €-8,901
19. Dec 18 Buy Susan Washer Individual 14. Dec 18 14. Dec 18 2,380 €2.96 €7,038
X
Management checks
We assess Applied Genetic Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Applied Genetic Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company’s lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.

Details
Name: Applied Genetic Technologies Corporation
2GT
Exchange: DB
Founded: 1999
$73,493,265
18,165,054
Website: http://www.agtc.com
Address: Applied Genetic Technologies Corporation
14193 NW 119th Terrace,
Suite 10,
Alachua,
Florida, 32615,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM AGTC Common Shares Nasdaq Global Market US USD 27. Mar 2014
DB 2GT Common Shares Deutsche Boerse AG DE EUR 27. Mar 2014
Number of employees
Current staff
Staff numbers
78
Applied Genetic Technologies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:41
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/15
Last earnings filing: 2019/02/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.